By integrating anatomy, pathophysiology, and modern clinical practice, this article aims to equip healthcare professionals with the knowledge required to effectively prevent, identify, and manage chronic RYGB-related complications
They coordinate the temporal recruitment of immune cell subsets and facilitate the progression from acute to chronic inflammation (Nedoszytko et al., 2014)
Anti-obesity medicines, based around incretin receptor agonists and their novel combination with other appetite regulatory targets, have weight reduction efficacy in this population, addressing obesity-related cardiometabolic complications while preserving skeletal muscle mass
Empagliflozin was originally developed as a diabetes medication but can be helpful in patients with heart failure and CKD
Participants lose up to 15% of their body weight over a year